Results 231 to 240 of about 73,189 (295)

Immune Evasion in Stem Cell-Based Diabetes Therapy-Current Strategies and Their Application in Clinical Trials. [PDF]

Biomedicines
Mu-U-Min RBA, Diane A, Allouch A, Al-Siddiqi HH.   +3 more
europepmc   +1 more source

Reconstruction of deep and perforating corneal defects in dogs—A review (Part I/III): Autogenous ocular tissues, donor tissues, and corneal clarity scoring

Veterinary Ophthalmology, Volume 28, Issue 2, Page 519-531, March 2025.
Abstract Corneal reconstruction is a key part of veterinary ophthalmic practice and numerous reconstructive techniques have been described for use in small animals in the peer‐reviewed veterinary literature written in English. Despite the evidence accrued over the last six decades in over 40 clinical articles and numerous other publications on ocular ...
Rick F. Sanchez, Eric C. Ledbetter, Marta Leiva   +2 more
wiley   +1 more source

Adjuvant conditioning shapes the adaptive immune response promoting immunotolerance via NLRP3/interleukin-1. [PDF]

iScience
Boccia T, Pan W, Fattori V, Cervantes-Diaz R, Rogers MS, Zanoni I, Cuenca AG.   +6 more
europepmc   +1 more source

Reconstruction of deep and perforating corneal defects in dogs—A review (Part II/III): Biomaterials and keratoprosthesis

Veterinary Ophthalmology, Volume 28, Issue 2, Page 532-542, March 2025.
Abstract The surgical reconstruction of severe corneal ulcers is a common and crucial component of the clinical practice of veterinary ophthalmology. Numerous surgical techniques are used in dogs for corneal reconstruction, and these techniques may be categorized by the material used to repair the corneal lesion.
Eric C. Ledbetter, Rick F. Sanchez, Marta Leiva Repiso   +2 more
wiley   +1 more source

Donor liver natural killer cells ameliorate liver allograft rejection via inducing apoptosis of alloreactive CD8⁺ T cells generating CD4⁺CD25⁺ regulatory T cells. [PDF]

Sci Rep
Yu J, Wu J, Long T, Lv L, Chen Z, Lin Z, Zhu H, Li G, Wan Y.   +8 more
europepmc   +1 more source

Transforming Growth Factor‐Beta Signaling in Cancer: Therapeutic Implications, Challenges, and Pathways to Progress

MedComm – Oncology, Volume 4, Issue 3, September 2025.
TGF‐β inhibition is emerging as a promising cancer therapy, yet translating laboratory success to bedside implementation has suffered significant setbacks. The associated challenges include adverse drug reactions, inadequate predictive models, and activation of alternative signaling pathways.
Faizah A. Alabi, Izuchukwu F. Okpalanwaka, Adenike Oyegbesan, Ebenezar Okoyeocha, Mariam Oladejo, Sikiru O. Imodoye   +5 more
wiley   +1 more source

Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation. [PDF]

Curr Oncol
Ran WJ, Xu LP, Zhang XH, Chang YJ, Mo XD, Sun YQ, Huang XJ, Wang Y.   +7 more
europepmc   +1 more source

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics

MedComm – Oncology, Volume 4, Issue 3, September 2025.
Immune checkpoints in tumor immunotherapy. Ligand binding to the receptor inhibits immune cell function, promotes tumor cell immune escape, and suppresses the immune response. The pathways of action are VISTA‐IGSF11, TIM‐3‐Ceacam1, CD47‐SIRPα, CTLA‐4‐CD80/CD86, PD‐L1‐PD‐1, MHC‐1‐LILRB, and CD24 ‐ Siglec ‐10. There are also other immune checkpoints such
Han Sun, Dan Huang, Huiling Zhang, Mingyuan Dong, Simiao Wang, Man Sun, Jiayi Liu, Yiqi Wang, Xiaojie Qu, Xuefeng Li, Zhaogang Yang   +10 more
wiley   +1 more source

Gene Editing: An Effective Tool for the Future Treatment of Kidney Disease. [PDF]

J Inflamm Res
Cao ML, Han RY, Chen SD, Zhao DY, Shi MY, Zou JH, Li L, Jiang HK.   +7 more
europepmc   +1 more source

Progress in homotransplantation of the liver. [PDF]

, 1966
Marchioro, TL, Porter, KA, Starzl, TE
core